[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National University of Malaysia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":656},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,51,74,100,126,149,165,191,214,242,281,308,338,362,391,414,436,455,473,494,521,548,571,599,621],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100053556","cognitive-care-bundle-for-ischaemic-stroke--a-pilot-randomised-controlled-trial-100053556",false,"NCT07610291","Cognitive Care Bundle for Ischaemic Stroke : A Pilot Randomised Controlled Trial","Application of Cognitive Care Bundle to Ischaemic Stroke Patients and Its Effect on Post-Stroke Cognitive Outcome: A Pilot Randomised Controlled Trial","COGIS","Inclusion Criteria:\n\n1. Age 18 years old or older\n2. Diagnosis of ischemic stroke within 7 days\n3. Mild cognitive impairment noted during admission of stroke (MoCA 18-25)\n\nExclusion Criteria:\n\n1. GCS \\\u003C8\n2. Pre-stroke neurodegenerative disease (Parkinson's, Alzheimer's, Vascular Dementia, Frontotemporal Dementia, Mixed Dementia, Lewy Body Dementia)\n3. Patient with previous stroke\n4. Modified Rankin Scale of 4 and above\n5. Known psychiatric disorder\n6. Patient on psychotherapy medications (benzodiazepine, antidepressant, etc)\n7. Severe aphasia\n8. Logistical issues hindering follow up\n9. Delirium","ALL","18 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if a set of treatments, called a \"cognitive care bundle,\" can help preserve cognitive ability in people who have had a stroke. This study will also test how feasible it is for people to follow this care bundle.\n\nThe main questions it aims to answer are:\n\n1. Do people find it feasible to follow the care bundle, which includes daily home blood pressure checks (and blood sugar checks for those with diabetes), along with referrals to specialists like dietitians, eye doctors, hearing specialists, and mental health professionals?\n2. Do people who receive the cognitive care bundle have better cognitive scores 3 months after their stroke, compared to those who receive standard care?\n\nResearchers will compare two groups of stroke survivors. One group will receive the cognitive care bundle plus standard medical care. The other group will receive standard medical care alone. This comparison will help researchers see if the care bundle works better to prevent cognitive decline.\n\nParticipants in the intervention (care bundle) group will:\n\nCheck and record their blood pressure daily at home (and their blood sugar too, if they have diabetes). Talk with a doctor weekly over the phone to review their readings and adjust medications if needed\n\nSee a dietitian for a personalized eating plan\n\nHave a hearing test by an audiologist\n\nHave a basic vision test by the research team\n\nAnswer a short questionnaire about their mood to screen for depression\n\nAll participants (in both groups) will undergo physiotherapy and cognitive training. Participants will be followed up with blood tests, examination by a doctor and questionnaires after 3 months.\n\nThis is a pilot study to see if this approach works and is practical to do in a larger future study.",[28,29],"Ischaemic Stroke","Cognitive Impairment, Mild",[31,32,33,34,35,36,37],"post-stroke cognitive impairment","care bundle","pilot","intervention","cognitive rehabilitation","blood pressure","hyperglycaemia","NOT_YET_RECRUITING","2026-07-10",{"date":41,"type":42},"2026-07-13","ACTUAL",{"date":44,"type":22},"2026-06",{"date":46,"type":22},"2029-04",{"name":48,"class":49},"National University of Malaysia","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100626187","intrapleural-alteplase-tyloxapol-vs-intrapleural-alteplase-dnase-in-pleural-infection-100626187","NCT07432373","Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","Comparative Analysis of Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection (ALTON-PI)","ALTON-PI","Inclusion Criteria:\n\nInclusion Criteria\n\n1. Adult patient aged ≥ 18 years old\n2. Patients with pleural infection (complex parapneumonic effusion or empyema) with poor pleural fluid drainage of ≤ 150 ml after 24 hours of chest drain insertion received either t-PA-DNAse or t-PA\u002FTyloxapol.\n3. Clinical features consistent with pleural infection; fulfilling ≥ 2 of the following characteristics:\n\n   i) Clinical evidence of infection, such as fever and or elevated C-reactive protein (CRP) or total white blood count (TWBC) ii) Complex pleural effusion proven by thoracic ultrasound is defined as the presence of fibrin strands or septations within the pleural cavity iii) Pleural fluid that fulfils at least one of the characteristics:\n   * Frank Pus,\n   * Exudative type of pleural effusion (according to light's criteria)\n   * Gram stain or culture positive\n   * Lactate dehydrogenase (LDH) \\> 900U\u002FL\n   * Acidic with pH \\\u003C 7.2\n   * Glucose level \\\u003C 3.3 mmol\u002FL\n\nExclusion Criteria:\n\n1. Incomplete data.\n2. Medical records that cannot be retrieved.",{"count":60,"type":22},80,"OBSERVATIONAL","Pneumonia, thought to be the chief aetiological process in the development of pleural space infection, is defined as an infection of the lung parenchyma with an estimated annual incidence rate of 5-11 cases per 1000 population, with around 50,000 hospital admissions in the U.K. per year. Parapneumonic effusions caused by an infection of the pleural membranes occur in 40-57% of cases of pneumonia. A variable percentage (10-20%) of parapneumonic effusions progresses to empyema (pus) and\u002For abscess formation (encapsulation). Pleural infection is associated with significant morbidity and mortality, which may be as high as 20-35% in immunocompromised patients.\n\nStandard treatment of these collections in adults involves antibiotic therapy, adequate drainage of infected fluid, and surgical intervention if conservative management fails. Appropriate treatment is adequate drainage via an intercostal catheter (ICC) with antibiotic therapy for parapneumonic effusions requiring clearance. Frequently, simple ICC drainage is ineffective due to the presence of loculations, formed predominantly by fibrinous material deposited in the fibrinopurulent phase of empyema, preventing free drainage of infected pleural fluid. The presence of fibrinous septae in the pleural space, known as loculations, may result in inadequate drainage of effusions and, therefore, nonresolution of infection and systemic sepsis. Surgical intervention (VATS or open) is usually required to clear loculations and resolve infection without adequate intercostal catheter drainage.\n\nAlthough the success rate of surgical intervention remains high, the morbidity and mortality of both VATS and open thoracotomy are of concern, particularly in a cohort of patients who may be older and with significant comorbidity. Less invasive therapies, which promote pleural space drainage and effective resolution of pleural infection, are therefore likely to be of considerable clinical utility.\n\nThe MIST 2 trial has established intrapleural therapy as the mainstay of CPEE treatment, hence avoiding surgery and decreasing the length of hospitalization; however, little is known about the correct dosage needed for tPA and Dornase Alfa\u002FDeoxyribonuclease (DNase). Dose and duration of intrapleural therapy based on MIST 2 involve multiple dosing and can be time-consuming for health care providers. Nevertheless, treatment of pleural infection with fibrinolytic therapy has been incorporated in the British Thoracic Society guideline 2023.\n\nAnother study in 2022 by Cheong et al. used a modified regimen of intrapleural alteplase 16 mg t-PA with 5 mg DNase for three doses administered sequentially within 24 h. In this study, a modified regimen of t-PA and DNase offers an alternative therapeutic option for patients who are unfit or refuse surgical intervention but have persistent pleural infection. They have demonstrated similar treatment success comparable to other studies, as evidenced by improved pleural fluid drainage and reduced pleural opacity on day 7 chest x-ray, approximately 50% from the baseline. The mechanism of action of t-PA and DNase in the pleural cavity remains unclear. Studies suggested that IPFT may trigger the monocyte chemoattractant protein 1 (MCP-1) pathway, which promotes pleural fluid formation and subsequently causes a therapeutic lavage effect that increases pleural fluid drainage.",[64],"Pleural Infection","RECRUITING","2026-06-29",{"date":68,"type":42},"2026-06-30",{"date":70,"type":42},"2026-04-01",{"date":72,"type":22},"2028-07-01",{"name":48,"class":49},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":18,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100641902","effectiveness-patient-acceptance-and-cost-estimation-of-3d-printed-retainer-compared-to-hawley-retainer-in-expansion-case-a-randomized-controlled-trial-100641902","NCT07659041","Effectiveness, Patient Acceptance, and Cost Estimation of 3D-printed Retainer Compared to Hawley Retainer in Expansion Case: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 16 years or older at the time of debonding\n* Treatment plan of extraction or non-extraction followed by straight wire appliances in the upper arch only or both arches\n* Undergone expansion treatment in the upper arch causing an arch width increase of 3-10mm, either using a Quadhelix, expansion with archwires, or URA with midline screw\n* Had pretreatment dental cast\n* Had no chronic medical condition.\n\nExclusion Criteria:\n\n* Cleft lip and palate\n* Chronic medical conditions\n* Broken teeth or bubbles on study model at site of measurement.",true,"16 Years",{"count":83,"type":22},28,[25],"Expansion of the arches is generally considered highly unstable and prone to relapse regardless of the type of expansion. Retention appliances play a vital role in preserving these changes. Hawley retainer users often avoid wearing them due to speech difficulties and less aesthetic appeal. They are also more prone to breakage, costlier, and require more labour. Despite the relatively recent introduction of 3D-printed retainers, they offer potential advantages in orthodontics, including the accuracy of digitally scanned images, reduced labour and material costs, and improved patient comfort. While 3D-printed retainers are quite new, most studies focus on laboratory testing of their mechanical properties, there is limited evidence directly comparing their effectiveness in retaining arch width increases, patient acceptance, and cost estimation. This knowledge gap creates uncertainty about the optimal choice of retainer for long-term stability, necessitating a comparative assessment of their performance. This study addresses this knowledge gap by evaluating the retention of arch width increases achieved using Hawley retainers versus 3D-printed retainers",[87,88],"Orthodontic Relapse","Retention in Orthodontic",[90,91],"orthodontic","3D printed retainer","2026-06-15",{"date":94,"type":42},"2026-06-22",{"date":44,"type":22},{"date":97,"type":22},"2027-12",{"name":48,"class":49},3,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":80,"sex":107,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100594867","fetal-growth-restriction-a-case-control-study-100594867","NCT07025031","Fetal Growth Restriction a Case Control Study","Maternal Serum Progesterone And Placental Heme Oxgenase-1 Expression In Early Onset Idiopathic Fetal Growth Restriction: A Case Control Study","Inclusion Criteria:\n\n* singleton\n* dated pregnancy\n\nExclusion Criteria:\n\n* fetus with structural or chromosomal anomaly\n* receive treatments such as aspirin, progestogen, low molecular weight heparin\n* has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes\n* smoking\n* suspected intrauterine infection","FEMALE","19 Years",{"count":110,"type":22},58,"The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.",[113],"Idiopathic Fetal Growth Restriction",[115,116,117],"progesterone","Heme Oxygenase-1","Idiopathic fetal growth restriction",{"date":119,"type":42},"2026-06-16",{"date":121,"type":42},"2025-07-01",{"date":123,"type":22},"2027-04-01",{"name":48,"class":49},2,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":80,"sex":18,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":50},"100643280","tocotrienol-supplementa-as-a-senolytic-agent-in-middle-aged-adults-100643280","NCT07637487","Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Evaluating Tocotrienol-Rich Fraction as a Senolytic Agent in Middle-Aged Adults","Inclusion Criteria:\n\n* Generally healthy as assessed by physical examination and blood lab test, including adequate liver and renal function, Neutrophil count \\> 1500\u002Fmm3, Platelet count 120,000 - 450,000\u002Fmm3, Haemoglobin concentration 11.5 to 19.0g\u002FdL for men; 10.5-17.5 g\u002FdL for women, Prothrombin and partial thromboplastin time within normal range, ALT and AST \\\u003C 80 IU\u002FL, Creatinine 0.7 to 1.3 mg\u002FdL\n* Subject of either gender, 35 to 64 years of age (inclusive)\n* Not allergy to palm oil and vitamin E\n* Do not take vitamin E supplements over the past 3 months\n* Provide written informed consent prior to screening\n* Subject is willing and able to comply with the study visit schedule and procedure, geographic proximity (investigator's discretion) that allows adequate follow up\n* Subjects understand the study protocol and signed informed consent forms\n\nExclusion Criteria:\n\n* Subjects with fat malabsorption\n* Subjects with chronic conditions such as cardiac diseases (heart failure, myocardial infraction, ischemic heart disease), neurological diseases, diabetes, HIV infection, psychiatric illness\u002Fsocial situations\n* Subjects with vegan diet\n* Current smoker or used to smoke in the past 3 months\n* Subject for surgery or had undergone surgery in the past 3 months\n* Current or past history of drug, alcohol abuse and cancer\n* Pregnant and lactating women\n* History of bleeding tendencies or any condition predisposing to bleeding e.g. thrombocytopenia, abnormal liver function, liver disease (e.g. chronic hepatitis), gastrointestinal ulcers\n* Any subject taking antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols\n* Subjects who are pre-disposed to inherited blood\u002Fcirculation disorders\n* Subject who is taking anticoagulants and antithrombotic drugs, e.g. warfarin, aspirin, ticlopidine, heparin, etc.","35 Years","50 Years",{"count":136,"type":22},220,[25],"The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are:\n\nDoes tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction?\n\nWhat health changes or medical issues occur in participants taking tocotrienol?\n\nResearchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways.\n\nParticipants will:\n\nTake tocotrienol (200 mg\u002Fday) or a placebo daily for 6 months\n\nAttend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests\n\nUndergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density.\n\nComplete questionnaires related to diet throughout the study period\n\nThis study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.",[140],"Healthy","2026-06-04",{"date":143,"type":42},"2026-06-09",{"date":145,"type":42},"2023-10-31",{"date":147,"type":22},"2027-01-30",{"name":48,"class":49},{"id":150,"slug":4,"hasResults":12,"nctId":13,"briefTitle":151,"officialTitle":152,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":26,"conditions":155,"keywords":157,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":164,"locationsCount":50},"100640607","COGnitive Care Bundle for Ischaemic Stroke : a Pilot Randomised Controlled Trial","APPLICATION OF COGNITIVE CARE BUNDLE TO ISCHAEMIC STROKE PATIENTS AND ITS EFFECT ON POST-STROKE COGNITIVE OUTCOME: A PILOT RANDOMISED CONTROLLED TRIAL",{"count":21,"type":22},[25],[28,156],"Cognitive Impairments, Mild",[158],"post-stroke cognitive impairment, care bundle, pilot, intervention, cognitive rehab, blood pressure, hyperglycaemia","2026-05-20",{"date":161,"type":42},"2026-05-27",{"date":44,"type":22},{"date":46,"type":22},{"name":48,"class":49},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":80,"sex":107,"minAge":108,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":50},"100612304","metabolic-availability-of-methionine-in-tempeh-chips-among-reproductive-age-women-using-indicator-amino-acid-oxidation-iaao-method-100612304","NCT07251842","Metabolic Availability of Methionine in Tempeh Chips Among Reproductive-age Women Using Indicator Amino Acid Oxidation (IAAO) Method","Understanding the Metabolic Availability of Methionine in High Calcium Tempeh (TempeCalTM) Chips Among Reproductive-Age Women by Using the Stable Isotope Technique","IAAO","Inclusion Criteria:\n\n* Universiti Kebangsaan Malaysia Kuala Lumpur campus female students and staffs aged 19 - 30 years old\n* Malaysian\n* Have consistent weight in the past 6 months\n* Have a normal body fat percentage (20% - 29.9%)\n\nExclusion Criteria:\n\n* Pregnant women\n* Lactating women\n* Reported serious medical or surgical ailments 3 months prior to start of the study\n* On dietary or nutrient supplements or who had taken antibiotics 4 weeks before the initiation of the study\n* Smoking\n* Allergy to soybean\n* Excessively high protein intake in the past 6 months","30 Years",{"count":175,"type":22},6,[25],"The goal of this study is to determine the protein quality of soybean tempeh in the form of chips. The main objective of this study is to determine how much methionine in tempeh can be used by reproductive-age women using the stable isotope method. The tempeh will be studied in the form of chips.\n\nThis research is being done to bridge the gap between the knowledge of protein requirements and the amount of food needed to meet those requirements. Results from this study will be important to confirm the protein quality of tempeh and thus provide a new alternative good protein source for humans, especially vegetarians and those with low socioeconomic status.\n\nEach participant will undergo seven experimental trials randomly. During four experimental trials, methionine intake will be obtained from a crystalline amino acid mixture, and during another three experimental trials, it will be obtained from tempeh chips. Each experimental trial will take three days, consisting of two adaptation days and one study day. During the two adaptation days, four equal meals per day will be consumed by the participants at their own place. On the study day, participants will need to come to the research unit of the National University of Malaysia, Kuala Lumpur campus, to consume nine hourly meals. In addition, during the study day, participants will also need to have their breath samples collected, their expired carbon dioxide rate measured, and consume a stable isotope.",[179],"Healthy Women of Child Bearing Potential",[171,181,182],"Metabolic availability","tempeh","2026-04-06",{"date":185,"type":42},"2026-04-08",{"date":187,"type":22},"2026-06-20",{"date":189,"type":22},"2026-10-20",{"name":48,"class":49},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":50},"100631633","sleep-optimization-with-acoustic-therapy-100631633","NCT07503223","Sleep Optimization With Acoustic Therapy","Sleep Optimization With Acoustic Therapy: A Polysomnography-Based Pre-Post Study","SONATA","Inclusion Criteria:\n\n* Adults aged 18-60 years\n* With sleep disturbances based on the PSQI score of \\>5 and\u002For ISI score \\> 15\n\nExclusion Criteria:\n\n* Central sleep apnea\n* Epilepsy\n* Current use of sedative-hypnotics or neurostimulation devices\n* Shift workers (people with different working hours patterns, for example morning, afternoon, night shifts)\n* Pregnancy\n* Moderate to severe OSA (AHI \\>15)\n* Presbycusis or other significant hearing loss\n* Patients with psychiatric disorder","60 Years",{"count":201,"type":22},40,[25],"Insomnia is a highly prevalent sleep disorder characterized by persistent difficulty initiating or maintaining sleep, often accompanied by impaired daytime functioning. Chronic insomnia affects approximately 10-15% of the adult population and is associated with significant physical, psychological, and socioeconomic burden. Traditional management strategies, including cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, have shown varying levels of effectiveness, with some patients remaining refractory to standard interventions or experiencing unwanted side effects.\n\nRecent advances in sleep neuroscience have revealed that disturbances in endogenous brain rhythms, particularly reductions in slow-wave activity (SWA) and altered sleep spindle patterns, play a key role in the pathophysiology of insomnia. These findings have sparked interest in non-pharmacological neuromodulation approaches to restore healthy sleep architecture.\n\nOne such approach is personalized nocturnal sound frequency therapy, in which low-frequency auditory stimuli (e.g., pink noise or slow oscillation-matched tones) are delivered during sleep to entrain and enhance specific sleep-related brain oscillations. Studies in healthy individuals and patients with insomnia have demonstrated that such stimulation can augment slow-wave sleep (N3), reduce nocturnal arousals, and improve perceived sleep quality. Personalized algorithms that adapt sound delivery based on real-time EEG signals further enhance these devices' efficacy and user experience.\n\nDespite growing evidence supporting the utility of sound-based sleep modulation, there is limited data on its application in diverse insomnia subtypes and its effect as measured by gold-standard sleep studies such as polysomnography (PSG). This study uses a pre-post PSG design to evaluate the impact of personalized sound frequency therapy on objective sleep architecture and subjective sleep outcomes in patients with insomnia. The findings may provide new insights into the therapeutic potential of acoustic brainwave modulation and support its integration into personalized insomnia care.",[205,206],"IMSOMNIA","Sleep Disturbance","2026-04-05",{"date":209,"type":42},"2026-04-07",{"date":70,"type":42},{"date":212,"type":22},"2028-01-01",{"name":48,"class":49},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":80,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":230,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":50},"100629137","comparative-study-between-combined-video-laryngoscope-and-video-stylet-intubation-versus-combined-video-laryngoscope-and-fiberoptic-intubation-in-a-simulated-difficult-airway-100629137","NCT07470736","Comparative Study Between Combined Video Laryngoscope and Video Stylet Intubation Versus Combined Video Laryngoscope and Fiberoptic Intubation in a Simulated Difficult Airway","Comparative Study Between Combined Video Laryngoscope and Video Stylet Intubation Versus Combined Video Laryngoscope and Fiberoptic Intubation","Inclusion Criteria:\n\n* the anaesthesiology medical officers who have at least more than two years of experience.\n\nExclusion Criteria:\n\n* Thsoe who has severe hand tremors.",{"count":222,"type":22},75,[25],"This study titled \"Comparative Study Between Combined Video Laryngoscope and Video Stylet Intubation Versus Combined Video Laryngoscope and Fibreoptic Intubation in a Simulated Difficult Airway\" aims to evaluate and compare two advanced intubation techniques used in managing difficult airways. Currently, there is no study in Malaysia that compares the combination of a video laryngoscope (VL) with a video stylet (VS) and the combination of VL with a fibreoptic bronchoscope (FOB). Although both methods have been investigated separately, direct comparisons in simulated difficult airway settings are limited. The findings of this study will help guide airway management protocols and improve clinical outcomes in challenging airway situations.\n\nThis is a single-centre, randomized comparative crossover trial conducted at the Department of Anaesthesiology and Intensive Care, HCTM, UKM. Ethical approval will be obtained from the departmental and university ethics committees prior to commencement. The study population will consist of anaesthesiology medical officers with at least two years of experience and anaesthesiology trainees in their second to fourth year of training at HCTM, UKM. Participants with severe hand tremors or those who decline participation will be excluded.\n\nThe main objectives are to compare the first-pass intubation success rate, time to successful intubation, and operator-rated ease of intubation between the two combined techniques. Each participant will perform both VL with VS and VL with FOB intubations in a simulated difficult airway scenario. The study hypothesizes that the combined VL with VS technique will provide superior performance, a higher first-pass success rate, shorter intubation time, and greater ease of use compared to the VL with FOB technique.\n\nParticipants who fail to complete all procedures or withdraw after participation will be considered dropouts. The results from this study are expected to provide useful insights into the effectiveness and practicality of these two combination techniques for airway management training and clinical application.",[226,227,228,229],"Video Laryngoscope","Airway","Difficult Airway","Fiberoptic Guided Intubation",[231,232,233,227],"Video laryngoscope","Video sylet intubation","Simulated difficult airway","2026-03-13",{"date":236,"type":42},"2026-03-17",{"date":238,"type":42},"2026-02-26",{"date":240,"type":22},"2028-03-14",{"name":48,"class":49},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":258,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":50},"100605044","effect-of-a-plant-focused-diet-on-nutritional-status-in-malnourished-peritoneal-dialysis-patients-100605044","NCT07157397","Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients","Effect of Plant-Focused Diet on Nutritional Status of Malnourished Patients Undergoing Peritoneal Dialysis in a Selected Hospital Care Setting","Inclusion Criteria:\n\n* Adult outpatients (\\>18 years old), attending HTCM PD clinic visits\n* Have undergone peritoneal dialysis for at least 6 months\n* Have a serum albumin level \\\u003C40 g\u002FL\n* Have a BMI of \\\u003C 25 kg\u002Fm2\n* Have a malnutrition inflammation score (MIS) of mild, moderate or severe\n* Agreed to follow the dietary instructions based on the randomization assignment\n* Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls\n\nExclusion Criteria:\n\n* Have been hospitalized for the past 3 months\n* Have ongoing infection\u002Fsepsis\n* Has undergone surgery in the past 6 months\n* Have high inflammatory diseases, malignancy, or cancer\n* Have dialysis adequacy of \\\u003C1.2 Kt\u002FV",{"count":250,"type":22},100,[25],"The goal of this clinical trial is to determine whether a plant-focused diet improves nutritional and health outcomes of malnourished adults undergoing peritoneal dialysis (PD). It will also learn about the safety of this diet in this population.\n\nThe main questions it aims to answer are:\n\n1. Does a plant-focused diet improve nutritional status compared to a standard kidney diet in PD patients?\n2. What changes occur in anthropometric, biochemical, and dietary measures over 6 months?\n\nResearchers will compare the plant-focused diet to a standard-of-care renal diet to see which is more effective in improving nutrition in PD patients.\n\nParticipants will:\n\n* Be randomly assigned to follow the plant-focused diet or the standard diet.\n* Be monitored for 6 months through in-person visits (aligned with their routine clinic appointments) and virtual check-ins via messages or calls.\n* Have their progress monitored for changes in outcomes such as nutrition, blood tests, kidney function, and quality of life.",[254,255,256,257],"End Stage Renal Disease (ESRD)","End Stage Kidney Disease (ESRD)","Peritoneal Dialysis (PD)","Malnourished",[259,260,261,262,263,264,265,266,267,268,269,270,271,272],"Peritoneal Dialysis","End Stage Renal Disease","End Stage Kidney Disease","Malnutrition","Plant-Focused Diet","Plant-Based Diet","Nutritonal Status","Dietary Counselling","Quality of Life","Physical Fitness","Inflammation","Appetite","Malaysia","Nutritional Intervention","2026-03-12",{"date":275,"type":42},"2026-03-16",{"date":277,"type":42},"2026-03-10",{"date":279,"type":22},"2027-03-31",{"name":48,"class":49},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":173,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":294,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":50},"100623489","evaluating-the-impact-of-a-mental-health-app-on-depression-and-resilience-among-medical-students-100623489","NCT07397299","Evaluating The Impact of A Mental Health App on Depression and Resilience Among Medical Students","Evaluating The Impact of A Mental Health App on Depression and Resilience Among Medical Students: A Randomized Controlled Study","Inclusion Criteria:\n\n* Aged 18 to 30;\n* Enrolled in medical school (preclinical or clinical years);\n* Owns a smartphone;\n* Able to read and understand English.\n\nExclusion Criteria:\n\n* Does not consent to study.",{"count":136,"type":22},[25],"This randomized controlled trial aims to determine whether access to a mental health app improves resilience and reduces depressive symptoms among medical students over a three-month period.\n\nCompared to the control group, researchers hypothesized that medical students in the intervention group are expected to show:\n\n* Significant reductions in depressive symptoms and greater improvements in resilience after three months of usage.\n* Significant reduction in thoughts of self-harm and anxiety, and improvement in self-esteem after three months of usage.\n\nResearchers will compare two groups to evaluate the app's impact on wellbeing:\n\n* Intervention group: Receives immediate full access to the mental health app.\n* Control group: Receives basic, without full access to the mental health app.\n\nParticipants will explore and experience the various features offered in the mental health app over a three-month period.",[292,293],"Depression - Major Depressive Disorder","Resilience",[295,296,297,298,299,300],"impact of mental health app","depression","resilience","medical students","effectiveness of mental health app","digital mental health intervention","2026-02-10",{"date":303,"type":42},"2026-02-13",{"date":305,"type":22},"2026-02-11",{"date":68,"type":22},{"name":48,"class":49},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":319,"conditions":320,"keywords":326,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":50},"100624273","phase-2-comparative-efficacy-of-intraductal-antibiotic-during-ercp-in-acute-cholangitis-100624273","NCT07407491","Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis","Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* The patients diagnosed with mild and moderate acute cholangitis based on TG 18\n* Planned for ERCP within 48 hours\n* 18 years old and above\n\nExclusion Criteria:\n\n* Severe acute cholangitis\n* History of antibiotic hypersensitivity\n* Receiving cancer chemotherapy, steroids, or immunosuppressive agents\n* Concomitant infections\n* Recent biliary interventions such as percutaneous transhepatic biliary drainage (PTBD) within last 3 months\n* Known or suspected perforated tympanic membrane, myasthenia gravis",{"count":316,"type":22},172,[318],"PHASE2","Does intraductal administration of antibiotics during endoscopic retrograde cholangiopancreatography (ERCP), in addition to standard systemic antibiotic therapy, improve clinical outcomes in patients with acute cholangitis compared with standard systemic antibiotic therapy alone?",[321,322,323,324,325],"Acute Cholangitis","Biliary Tract Infection","Biliary Obstruction","Choledocholithiasis","Malignant Biliary Stricture",[321,327,328,329,324],"ERCP","Intraductal antibiotics","Biliary tract infection","2026-02-05",{"date":332,"type":42},"2026-02-12",{"date":334,"type":42},"2024-07-09",{"date":336,"type":22},"2026-07-08",{"name":48,"class":49},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":345,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":50},"100620805","autologous-dentine-graft-compared-to-xenograft-in-managing-periodontally-compromised-second-molar-after-third-molar-removal-100620805","NCT07362394","Autologous Dentine Graft Compared to Xenograft in Managing Periodontally Compromised Second Molar After Third Molar Removal","Autologous Dentine Graft Compared to Xenograft in Managing Periodontally Compromised Second Molar After Third Molar Removal - A Split-Mouth Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 26 years and above who can give informed consent and are scheduled for bilateral surgical removal of mesioangular or horizontally impacted mandibular M3s\n* Present with a periodontally compromised mandibular second molar, defined by the presence of probing pocket depth (PPD) greater than 4 mm on the distal aspect\n* Type of impaction of M3s on both sides must be symmetrical\n* Consent to the use of xenograft as control\n\nExclusion Criteria:\n\n* Smokers\n* Poor oral hygiene with \\>30% full mouth plaque score (FMPS)\n* Pregnant or lactating mothers\n* Have uncontrolled systemic conditions such as diabetes or immunodeficiency disorders\n* On medications that affect bone metabolism, including bisphosphonates or corticosteroids\n* History of periodontal surgery or grafting at the intended surgical site\n* Presence of acute infection and M2s with distal caries and Grade III mobility","26 Years",{"count":5,"type":22},[25],"The goal of this study is to evaluate the efficacy of autologous dentin graft (ADG) in treating periodontal defects on the distal aspect of mandibular 2nd molar (M2) after surgical removal of impacted mandibular 3rd molar (M3) by improving periodontal and radiological outcomes when compared with a xenograft, which is commercially available. The main questions it aims to answer are:\n\n1. How does the clinical efficacy of ADG compare to xenografts, regarding wound healing and periodontal parameters at the distal aspect of periodontally compromised mandibular M2 following impacted M3 extraction?\n2. How does the radiological bone regeneration at ADG-grafted sites differ from that at xenograft-grafted sites?\n3. How do the post-operative patient-reported outcomes at sites receiving ADG differ from those at sites receiving xenografts?\n\nResearchers will compare ADG to xenograft to see if ADG is more efficacious in managing periodontal defects on distal aspect of M2 after surgical removal of M3.\n\nParticipants will\n\n1. Undergo bilateral surgical removal of M3 under general anaesthesia\n2. Receive ADG on test site and xenograft on contralateral control site\n3. Come back for clinical assessments, wound healing assessments and radiographic assessments for 5 times after the surgery (2 weeks, 1 month, 3 months, 6 months and 12 months)",[350,351,352,353],"Impacted Mandibular Third Molar Extraction","Dentin Graft","Xenograft","Bone Defects","2026-01-15",{"date":356,"type":42},"2026-01-23",{"date":358,"type":22},"2026-06-01",{"date":360,"type":22},"2028-06-30",{"name":48,"class":49},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":369,"minAge":173,"maxAge":134,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":50},"100602520","short-term-effects-of-sucralose-and-saccharin-on-blood-sugar-and-gut-microbiota-in-type-2-diabetes-100602520","NCT07124585","Short-Term Effects of Sucralose and Saccharin on Blood Sugar and Gut Microbiota in Type 2 Diabetes","Short-Term Effect of Non-Nutritive Sweeteners (Sucralose and Saccharin) Consumption on Glycaemic Control and Gut Microbiota in Type 2 Diabetes Patients","Inclusion criteria This study aims to recruit a cohort of patients with early-phase diagnosed T2DM whose conditions are stable that can best represent the Malaysian DM phenotypes.\n\n1. Male citizens of Malaysia.\n2. Aged between 30 and 59 years.\n3. BMI between 23-29.9 kg\u002Fm² (Overweight).\n4. Diagnosed with diabetes for a duration between 1-10 years.\n5. Currently on oral antidiabetic medications and not on insulin.\n6. Initial HbA1c less than 10%.\n7. Patients with other stable, non-severe chronic conditions (e.g., hypertension, dyslipidemia) may be included if they have been on a stable prescribed oral treatment for at least 6 months.\n8. Patients who have undergone dietary counselling for diabetes and are willing to maintain their habitual diabetes-friendly diet and usual physical activity patterns throughout the study period.\n9. Willing to refrain from alcohol throughout the study period.\n10. Must be literate in English or Bahasa Malaysia.\n\nExclusion criteria The exclusion criteria will primarily focus on lifestyle behaviours or dietary practices that deviate from typical Malaysian lifestyles and while also considering behaviours that could significantly alter the gut microbiota.\n\n1. Current smoking, alcohol use, or drug abuse.\n2. Experienced more than a 5% change in body weight within the past 3 months.\n3. Acute illness or significant cardiovascular, psychological, neurological, renal, or endocrine diseases, apart from diabetes.\n4. Intolerance or allergy to test products.\n5. Special dietary practices (e.g., intermittent fasting, vegetarian, ketogenic diet) that deviate from typical Malaysian dietary patterns.\n6. Treatment with glucocorticoids, antibiotics or other medications and food supplements (e.g. probiotics) that can significantly alter intestinal function and gut microbiome.\n7. Involvement in clinical trials within the last 3 months.","MALE",{"count":371,"type":22},33,[25],"This clinical trial investigates the short-term effects of two commonly used non-nutritive sweeteners (NNS), saccharin and sucralose, on blood glucose regulation and the gut microbiota in adults with Type 2 Diabetes Mellitus (T2DM). While NNS are widely promoted as sugar substitutes to aid glycaemic control, emerging evidence suggests that even small doses may influence metabolic health, potentially through interactions with the gut microbial community.\n\nThe study is designed as a double-blind, randomized, placebo-controlled, crossover trial involving 33 adults with T2DM. Each participant will receive all three interventions, saccharin, sucralose, and a placebo (calcium carbonate) in random order. Each intervention will be administered once daily in capsule form for 7 consecutive days, with a 4-week washout period between phases to minimize carryover effects.\n\nThroughout the trial, data will be collected on anthropometry, blood-based glycaemic biomarkers, dietary intake, physical activity, and stool samples. Gut microbiota composition will be assessed via 16S rRNA gene sequencing.\n\nThe primary aim is to generate evidence on whether short-term exposure to NNS can affect glycaemic outcomes and gut microbial profiles in individuals with T2DM. The findings are expected to support future dietary recommendations on NNS use and improve our understanding of diet-microbiota-host interactions, particularly within Asian populations.",[375],"Type 2 Diabetes Mellitus (T2DM)",[377,378,379,380,381,382],"Non-nutritive sweetener","artificial sweetener","gut microbiota","saccharin","sucralose","type 2 diabetes","2025-12-09",{"date":385,"type":42},"2025-12-10",{"date":387,"type":22},"2026-01-30",{"date":389,"type":22},"2027-07-31",{"name":48,"class":49},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":80,"sex":18,"minAge":397,"maxAge":19,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":125},"100613422","clinical-efficacy-evaluation-of-supraglottic-airway-device-safelm-in-paediatric-population-100613422","NCT07266389","Clinical Efficacy Evaluation of Supraglottic Airway Device SafeLM™ in Paediatric Population","Inclusion criteria\n\n* Patients who are scheduled for a surgery under general anaesthesia where supraglottic airway is deemed appropriate.\n* ASA I or II\n* Age up to 18 years old\n* Body weight of 10 kg and above\n\nExclusion criteria\n\n* Presence of risk of gastric regurgitation or aspiration\n* Recent upper respiratory tract infection within 2 weeks\n* Uncontrolled respiratory co-morbidity such as bronchial asthma, chronic lung disease, restrictive lung disease\n* Presence of congenital airway abnormalities\n* Patient or next of kins refusal in participating this study","0 Years",{"count":399,"type":22},60,[25],"The goal of this interventional study is to evaluate the clinical efficacy of SafeLM™, a video laryngeal mask airway device in paediatric population. The main questions it aims to answer are:\n\n1. To determine the success rate, ease of device insertion, time for insertion, and how well the device seals the airway by measuring the oropharyngeal leak pressure (OPLP) of SafeLM™.\n2. To determine the incidence of complication associated with SafeLM™ usage.\n3. To study the association of glottic view with success rate and rate of complication.\n\nParticipants perioperative clinical data will be collected for data analysis.",[403,404,405],"Anesthesia","Supraglottic Airway Efficiency","Paediatric Airway Management","2025-11-24",{"date":408,"type":42},"2025-12-05",{"date":410,"type":22},"2025-12-02",{"date":412,"type":22},"2026-05-30",{"name":48,"class":49},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":422,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":125},"100545093","efficacy--safety-of-dry-powder-ivy-extract-syrup-prospan-versus-nac-among-copd-patients-100545093","NCT06377410","Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients","A Randomised, Open Label, Interventional Study Evaluating the Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients (SyProNAC Trial)","SyProNAC","Inclusion Criteria:\n\n* Participants with documented post bronchodilator FEV1\u002FFVC \\\u003C 70 or \\\u003CLLN\n* Age 40 years and above\n* Able to perform spirometry\n* Participant with Stable COPD based on GOLD 2023 strategy\n\nExclusion Criteria:\n\n* Diagnosis of other chronic lung diseases: Asthma, Asthma-COPD Overlap, Interstitial Lung Disease, Bronchiectasis, Lung Cancer\n* Participants with contraindication for spirometry: recent cardiac complications, major surgery, severe advanced respiratory disease, or those with cognitively or neurologically impairment\n* Hypersensitivity to acetylcysteine or any component of the formulation\n* Hypersensitivity to dry powder ivy extract\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG (human Chorionic Gonadotropin) laboratory test\n* Participant on pre-existing regular mucolytics (at least 1 month prior)\n* Illiterate participants","40 Years",{"count":250,"type":22},[25],"As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD) affects more than 300 million people worldwide. These patients suffer from 0.5-3.5 exacerbations per year on average. Each exacerbations dampened their health status as well as quality of life, not to mention a great burden to our healthcare system. Those partially treated or prolonged exacerbations would subsequently lead to unfavorable disease progression. Hence a holistic approach in managing each exacerbations is very crucial.\n\nMucus hypersecretion in COPD patients plays a pivotal role in acute exacerbations and associated with unfavorable outcomes. These exacerbations comes with sputum increment as much as its purulence. Mucolytics are believed to to ease patient to expectorate and benefits them from tip into an exacerbations or even the consequent hospitalisation.\n\nMucolytics work by reducing sputum viscosity hence improved its expectoration. N-acetylcysteine (NAC) is a mucolytic with antioxidant and anti-inflammatory properties, commonly used in practice among COPD patients. Meanwhile, Syrup Prospan is ivy leaf preparations, obtained as extracts from leaves of the plant Hedera helix L. It is widely used over-the-counter cough remedy containing saponins which are believed to have expectorant properties. Studies show evidence of antispasmodic, bonchodilating, anti-inflammatory and antitussive properties and its usage is authorised by the European Medicines Agency .",[427],"Chronic Obstructive Pulmonary Disease","2025-11-17",{"date":430,"type":42},"2025-11-19",{"date":432,"type":42},"2024-05-01",{"date":434,"type":22},"2026-11-30",{"name":48,"class":49},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":50},"100540267","normal-saline-flushing-with-and-without-heparin-lock-in-maintaining-small-bore-intercostal-chest-catheter-icc-patency-100540267","NCT06314620","Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency","Safety And Efficacy Of 8 Hourly Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency ; A Prospective Pilot Study","SENSHIP","Inclusion Criteria:\n\n• All patients admitted in medical wards for pleural effusion who had small bore intercostal catheters inserted.\n\nExclusion Criteria:\n\n* Patients with hydropneumothorax with small bore intercostal catheters\n* Patients with septated effusion planned for intrapleural fibrinolysis\n* Patients with severe coagulopathy\n\n  * INR ≥ 1.5\n  * PT \\> 37s\n  * aPTT \\> 100s\n* Patients with thrombocytopenia of less than 50 x 109\u002FL\n* Patients who has not consented to be involved in the study\n* Patients with indwelling pleural catheters\n* Unconscious patients will be excluded from this study\n* Patients with poor GCS score will be excluded from this study",{"count":201,"type":22},[25],"Pleural diseases are among the most common clinical problems encountered in healthcare settings in Malaysia and even worldwide. Most patients presented in a hospital setting with pleural diseases will need pleural aspirations or thoracentesis and chest drains for a variety of reasons. Healthcare providers will often be exposed to patients requiring pleural drainage hence it is important to be aware of safe techniques and procedures of insertion and also maintaining the pleural drainage systems to yield beneficial results.\n\nMost often, smaller catheters were deemed to be less effective in view of slower drainage rates and associated with high risk of blockage. However presently , in tertiary hospital settings small bore intercostal chest catheters (SBICC) have become an alternative to large bore intercostal catheters (LBICC). SBICC has been found to be equally effective, less painful and easily tolerated by patients. Hence, proper maintenance of SBICC should be undertaken to reduce rates of occlusion and to yield most benefits from the pleural aspirations procedures.\n\nBritish Thoracic Society in their latest guidelines recommends the use of small bore intercostal chest drain as the first choice in draining pleural effusions.\n\nThe success of draining pleural effusions with a SBICC has shown variable rates of success among different studies conducted. Most common issues faced are drain blockage and drain dislodgement.\n\nThere is limited data comparing the use of normal saline flushing versus fibrinolytic drug lock in maintaining patency of small bore intercostal chest drains in draining pleural effusions. This has lead us in conducting this research to compare the rates of partial or complete occlusions among normal saline flush with and without heparin saline lock in maintaining the patency of small bore intercostal chest catheter among patients with pleural diseases in Hospital Canselor Tuanku Muhriz, UKM requiring chest drains insertion.",[448],"Pleural Effusion",{"date":430,"type":42},{"date":451,"type":42},"2024-03-15",{"date":453,"type":22},"2027-06-01",{"name":48,"class":49},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":50},"100535128","virtual-reality-distraction-during-small-bore-intercostal-chest-drain-insertion-100535128","NCT06247800","Virtual Reality: Distraction During Small Bore Intercostal Chest Drain Insertion","Virtual Reality: Satisfaction and Tolerability as a Distraction During Small Bore Intercostal Chest Drain Insertion an Open Label Randomized Control Trial","VR-STICH","Inclusion Criteria:\n\n* All participants undergoing ICC insertion\n* Participants who could understand and give consent\n\nExclusion Criteria\n\n* Participants who are unable to understand or give consent\n* Ventilated patients\n* Participants who are not comfortable wearing VR device\n* Participants who are unable to communicate (illiterate, had hearing impairment, mute, blind or had memory impairment)\n* Participants with craniofacial deformity\n* Participants who are on sedative medication\n\nTraumatic or post Motor Vehicular Accident patient Participants undergoing Indwelling pleural catheter insertion Participants with anxiety disorder\n\nExclusion Criteria:\n\n\\-",{"count":60,"type":22},[25],"Intercostal chest drain (ICC) insertion is a common procedure done worldwide to treat and diagnose pleural disease. It is used to evacuate fluid, blood, or air in the cavity from a myriad of causes namely pleural effusions of different etiologies, empyema, hemothorax, chylothorax and pneumothorax. It also functions as a route for antibiotics, pleurodesis and fibrinolytics. Hippocrates, whose practiced medicine 2,400 years ago, is often credited with being the first to insert a metal tube into the pleural region to drain fluid. It wasn't until the 19th century that a closed drainage system was properly documented in the literature, although open drainage remained to be the norm for quite some time.\n\nIn the past, large-bore tubes (24-32 F) were recommended in nearly all circumstances and were inserted using a blunt dissection technique. However, during the past two decades, small-bore catheters have become increasingly popular. They were first used to drain abdominal collections and have now been adopted for use in draining the pleural cavity utilizing the needle and guide wire Seldinger procedure, typically with radiological guidance. In addition to that, Seldinger technique allow us to insert the catheter at lower intercostals spaces without injury to the diaphragm or abdominal organs, thereby ensuring patient safety.",[448],{"date":430,"type":42},{"date":469,"type":42},"2024-02-01",{"date":471,"type":22},"2026-12-25",{"name":48,"class":49},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":50},"100559497","conventional-cpap-airsense-10-vs-portable-air-mini-cpap-for-obstructive-sleep-apnea-caspam-100559497","NCT06564896","Conventional CPAP Airsense 10 VS Portable Air-Mini CPAP For Obstructive Sleep Apnea (CASPAM)","Comparing A Conventional CPAP Airsense 10 VS Portable Air-Mini CPAP For Obstructive Sleep Apnea From Users' Perspective; A Cross - Over Study","CASPAM","Inclusion Criteria:\n\n* Aged ≥ 18 years.\n* Patients diagnosed with moderate to severe OSA (based on AHI classification from sleep study performed).\n* Patients who are able to understand and answer the questionnaire given.\n\nExclusion Criteria:\n\n* Patients who are unable to give consent to the study.\n* Patients who have been diagnosed with OSA and already on CPAP machine.\n* Patients who had underlying Obesity Hypoventilation Syndrome (OHS).\n* Patients who had underlying co-morbidities that worsen apnea symptoms, such as congestive cardiac failure, active malignancy, narcolepsy, active alcohol or drug abuse, treatment-refractory dementia, psychotic illness and active use of drugs that disturb the sleep architecture (i.e hypnotics or stimulants of central nervous system).",{"count":21,"type":22},[25],"Obstructive sleep apnea (OSA) has been one of the topmost global health problems. It is an underdiagnosed disease which have a huge burden on healthcare if left untreated. Almost 80-90% of adults are underdiagnosed of OSA Obesity primarily is one of the supreme risk factors for developing OSA. Globally, obesity cases have risen affecting almost two billion people. According to National Health and Morbidity Survey (NHMS) 2019, 1 in 2 adults in Malaysia were overweight or obese. Report from World Obesity Atlas 2023 predicts that adult obesity will rise 4.7% annually from 2020 - 2035, while child obesity will increase by 5.3% per year over similar timeline. Overweight individuals will have a significant economic impact on Malaysia's Gross Domestic Product (GDP) by 2035 by 2.8% which is estimated to be about RM 3.2 trillion.\n\nSequalae of OSA is divided into two (cardiovascular-metabolic effect and neurocognitive effect). This group of patients are at high risk of developing hypertension, insulin resistance, dyslipidemia which then leads to pulmonary hypertension and heart failure. More importantly, from the neurocognitive point of view, persistent sleep deprivation will lead to poor concentration, impaired memory, personality changes affecting overall self-performance which can lead to depression and compromising safety as they have higher risk of work-related accidents.",[485],"Obstructive Sleep Apnea","2025-10-05",{"date":488,"type":42},"2025-10-08",{"date":490,"type":42},"2024-09-01",{"date":492,"type":22},"2027-01-01",{"name":48,"class":49},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":50},"100608929","effect-of-probiotics-on-quality-of-life-activities-of-daily-living-and-anxiety-in-post-stroke-patients-100608929","NCT07207941","Effect of Probiotics on Quality of Life, Activities of Daily Living and Anxiety in Post Stroke Patients","Inclusion Criteria:\n\n* Patients diagnosed with moderate ischemic stroke with mRS score of 2-4 from onset of stroke up to 3 months.\n* Patients aged 18 to 80 years, who are able to read and write in English and\u002For Bahasa Malaysia\n* Provide informed consent\n\nExclusion Criteria:\n\n* Patients with aphasia\n* Patients who have received thrombolysis or mechanical thrombectomy\n* Gastrointestinal related diseases such as lactose intolerance, coeliac disease, Renal or hepatic insufficiency (Based on recent six-month blood profile)\n* Progressive neurological disease (Alzheimer's disease, Parkinson's Disease, Motor Neuron Disease)\n* Pregnancy and breastfeeding.\n* Secondary cause of stroke- vasculitis, cerebral venous sinus thrombosis, connective tissue disorders\n* Past history of psychiatric disorders (depression, anxiety)\n* Recent use of probiotics and allergies to probiotics\n* Immunosuppressed patients (HIV, malignancy)\n* Patient with septicemia","80 Years",{"count":502,"type":22},110,[25],"Research on Effect of probiotics on quality of life, activities of daily living and anxiety in post stroke patients",[506],"Stroke",[508,509,510,511,512],"stroke","probiotic","quality of life","anxiety","activities of daily living","2025-09-26",{"date":515,"type":42},"2025-10-06",{"date":517,"type":22},"2025-09-30",{"date":519,"type":22},"2028-05-31",{"name":48,"class":49},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":107,"minAge":528,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":537,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":50},"100540647","hydroxychloroquine-in-type-2-diabetes-during-pregnancy-100540647","NCT06319560","Hydroxychloroquine in Type 2 Diabetes During Pregnancy","Hydroxychloroquine as an Adjunct Therapy in the Management of Type 2 Diabetes in Pregnancy: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Singleton\n* Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus\n\nExclusion Criteria:\n\n* autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease\n* chronic kidney disease\n* fetal anomaly\n* women on steroid therapy\n* diabetic retinopathy\n* known thalassaemia or thalassaemia carrier","20 Years","45 Years",{"count":531,"type":22},56,[25],"The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy?\n* Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment",[535,536],"Diabetes in Pregnancy","Type 2 Diabetes",[538,539,540],"diabetes","pregnancy","hydroxychloroquine","2025-06-09",{"date":543,"type":42},"2025-06-12",{"date":545,"type":42},"2024-03-24",{"date":492,"type":22},{"name":48,"class":49},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":80,"sex":107,"minAge":19,"maxAge":529,"enrollmentInfo":555,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":557,"conditions":558,"keywords":561,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":50},"100464323","1-versus-2-hours-post-meal-glucose-monitoring-in-gestational-diabetes-on-treatment-100464323","NCT05326204","1 Versus 2 Hours Post Meal Glucose Monitoring in Gestational Diabetes on Treatment","1 Versus 2 Hours Post Meal Self Monitoring Blood Glucose in Gestational Diabetes Mellitus on Treatment-A Prospective Randomised Controlled Trial","Inclusion Criteria:\n\n* Gestational diabetes diagnosed based on National Institute for Health and Care Excellence guideline\n* requiring treatment either with metformin alone or combined with insulin\n\nExclusion Criteria:\n\n* type 1 and 2 diabetes\n* bad obstetrics history\n* underlying medical disorders such as Systemic Lupus Erythematosus\n* fetal anomaly\n* delivery elsewhere",{"count":556,"type":22},2954,"A study to compare between 1 and 2 hours post meal blood glucose monitoring in patients with Gestational Diabetes Mellitus requiring treatment.",[559,560],"Gestational Diabetes","Treatment Adherence",[562,563,564],"Gestational diabetes","treatment","glucose monitoring",{"date":543,"type":42},{"date":567,"type":42},"2021-12-30",{"date":569,"type":22},"2025-12-29",{"name":48,"class":49},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":50},"100570705","phase-1-autologous-cd19-car-t-cell-therapy-for-severe-refractory-systemic-lupus-erythematosus-sle-100570705","NCT06710717","Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)","Autologous CD19 Car T-Cell Therapy For Patients With Severe Refractory Systemic Lupus Erythematosus - A Pilot Study","Inclusion Criteria:\n\n\\-\n\nAged between ≥ 18 to ≤ 65 years Clinical Diagnosis of SLE according to the 2019 European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria (Fanouriakis et al., 2019) Positive anti-nuclear antibody (ANA) (titer ≥1:80 ), anti-dsDNA (≥30 IU\u002FmL on enzyme-linked immunosorbent assay \\[ELISA\\]), or anti-Smith at screening or by documented medical history Active disease (defined by not being in remission according to DORIS criteria or in a low disease activity state \\[LLDAS\\]) (Franklyn et al., 2016, van Vollenhoven et al., 2021) With at least one active organ system involvement Persistent active disease with insufficient response to glucocorticoids and at least 2 of the following treatments for at least 3 months each: cyclophosphamide, mycophenolate mofetil or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.\n\nSerum ALT \\\u003C5 times the normal value, serum bilirubin \\\u003C3 times the normal value, Left ventricular ejection fraction \\>45% Life expectancy of more than 3 months Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Psychological, sociological or geographical conditions precluding compliance A female of childbearing age must have a negative pregnancy test and is on two effective contraception methods A male must use two effective contraception methods\n\nExclusion Criteria:\n\n\\-\n\nActive cancer or receiving cancer treatment Evidence of severe lung, FVC \\\u003C45% and\u002For DLCO (corrected for Hb) \\\u003C30% predicted, heart (NYHA class III\u002FIV, arrhythmia, AV block, uncontrolled hypertension), liver failure or severe neurologic disorders.\n\nPre-existing irreversible kidney damage and creatinine clearance below 30 ml\u002Fmin ( to review) Severe pancytopenia HIV positivity. Active Hepatitis B, C infection. Septicemia. Pregnant\u002Fnursing female. Receiving stem cell transplant within 12 weeks of enrolment, chemotherapy or radiotherapy within 8 weeks of enrolment Active CNS involvement.","65 Years",{"count":580,"type":22},5,[582],"PHASE1","This pilot clinical study aims to evaluate the effectiveness of Chimeric Antigen Receptor (CAR) T-cell therapy in treating severe, refractory systemic lupus erythematosus (SLE), an autoimmune disease driven by autoreactive B-cells. Current treatments for severe SLE, including glucocorticoids, cytotoxic, and immunosuppressive drugs, have significant limitations. These treatments do not adequately control the underlying autoimmune process and require long-term use, leading to chronic side effects and often failing to prevent permanent organ damage. Given the high prevalence and mortality rates associated with SLE in regions like Asia and Malaysia, there is a pressing need for more effective therapies.",[585],"Systemic Lupus Erythematous (SLE)",[587,588,589,590],"CAR T cells","SLE","treatment-refractory","severe SLE","2025-05-22",{"date":593,"type":42},"2025-05-29",{"date":595,"type":42},"2025-01-03",{"date":597,"type":22},"2029-01-02",{"name":48,"class":49},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":606,"maxAge":578,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":50},"100357706","phase-2-intravenous-autologous-cd19-car-t-cells-for-rr-b-all-100357706","NCT03937544","Intravenous Autologous CD19 CAR-T Cells for R\u002FR B-ALL","A Phase II\u002FIII Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed\u002F Refractory B-Acute Lymphoblastic Leukaemia","Inclusion Criteria:\n\n* Patients with relapsed\u002Frefractory B-ALL in accordance with World Health Organization (WHO) classification by virtue of BM morphology, flow cytometry, cytogenetics and molecular genetics\n* Age between ≥13 to ≤ 65 years\n* No detectable leukaemia in the CSF (CNS-1)\n* CNS leukaemia without clinically evident neurological symptoms (CNS-2; with \\\u003C5 WBC per μL and cytology positive for blasts)\n* Adequate organ function as defined by a creatinine clearance \\> 50 ml\u002Fmin, serum total bilirubin \\\u003C 5 times the normal value, left ventricular ejection fraction \\> 40%\n* ECOG performance status ≤ 2\n* Life expectancy \\> 3 months\n* Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not receiving immunosuppression\n* Female patients of child bearing age must have negative pregnancy test and is on highly effective contraception methods\n* Male patients must use highly effective contraception methods\n\nExclusion Criteria:\n\n* Patients with CNS-3 leukaemia.\n* Active cancer (other than B-ALL).\n* Evidence of severe lung, heart (NYHA class III\u002FIV, arrhythmia, AV block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder.\n* Presence of active autoimmune disease or atopic allergy.\n* HIV serology positivity.\n* Active Hepatitis B or C infection as evidenced by quantitative viral PCR assay.\n* Uncontrolled sepsis\n* Pregnant \u002F nursing female.\n* Ongoing prednisolone \\> 1mg\u002Fkg daily or equivalent.\n* Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.","13 Years",{"count":608,"type":22},10,[318,610],"PHASE3","This is Phase II \u002F III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed \u002F Refractory B-Acute Lymphoblastic Leukaemia",[613,614],"Relapsed B Acute Lymphoblastic Leukaemia","Refractory B Acute Lymphoblastic Leukaemia",{"date":593,"type":42},{"date":617,"type":42},"2019-03-19",{"date":619,"type":22},"2027-03-18",{"name":48,"class":49},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":80,"sex":18,"minAge":19,"maxAge":628,"enrollmentInfo":629,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":638,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":653,"leadSponsor":655,"locationsCount":50},"100585701","artificial-intelligence-ai-technology-may-help-patients-to-understand-bowel-preparation-better-before-they-go-for-colonoscopythis-study-attempts-to-leverage-ai-chatbot-in-counselling-patients-to-improve-bowel-cleanliness-reduce-anxiety-as-well-as-increase-procedural-satisfaction-100585701","NCT06905782","Artificial Intelligence (AI) Technology May Help Patients to Understand Bowel Preparation Better Before They go for Colonoscopy.This Study Attempts to Leverage AI Chatbot in Counselling Patients to Improve Bowel Cleanliness, Reduce Anxiety as Well as Increase Procedural Satisfaction","Prospective Single Blinded Randomized Control Trial on the Effectiveness of Using Large Language Model Artificial Intelligence Chatbot to Improve Boston Bowel Preparation Score (BBPS) for Colonoscopy Preparation","Inclusion Criteria:\n\n* All scheduled colonoscopy with indication\n* Adequate digital literacy\n* Adequate language literacy with Malay and English language\n\nExclusion Criteria:\n\n* Patients with memory impairment due to previous stroke, dementia or Alzheimer's disease\n* Diagnosed with clinical anxiety","75 Years",{"count":630,"type":22},96,[25],"Traditional pre-colonoscopy counselling requires significant time from healthcare workers to explain procedures, limiting efficiency and patient turnover. Inadequate bowel preparation exacerbates this issue, leading to repeat procedures and increased costs. However, no study has yet evaluated the effectiveness of AI in improving the Boston Bowel Preparation Scale (BBPS) for colonoscopy preparation. By addressing this gap, AI chatbots could provide personalized guidance, reduce healthcare worker burden, improve preparation quality, and enhance patient experience.This research attempts to evaluate the effectiveness of using Artificial intelligence (AI) chat bot to improve bowel preparation, anxiety level and patient's satisfaction among colonoscopy patients in Hospital Tuanku Muhriz (HCTM), compared to conventional instructions",[634,635,636,637],"Colorectal Cancer Screening","Colon Polyps and Adenomas","Bowel Preparation Quality","Artificial Intelligence (AI)",[639,640,641,642,643,644,645,646,647,648],"colorectal cancer","colon polyp","colonoscopy","bowel preparation","Boston Bowel Preparation Score (BBPS)","artificial intelligence","AIChatbot","large language model","patient satisfaction","cancer screening","2025-03-24",{"date":651,"type":42},"2025-04-01",{"date":651,"type":22},{"date":654,"type":22},"2026-02-02",{"name":48,"class":49},""]